Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

101. Randomised controlled trial: Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation

Randomised controlled trial: Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation Article Text Therapeutics Randomised controlled trial Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation Brennan Spiegel

Evidence-Based Medicine (Requires free registration)2011

102. Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Rifaximin therapy for patients with irritable bowel syndrome without constipation. 21208106 2011 01 06 2011 01 12 2015 06 24 1533-4406 364 1 2011 Jan 06 The New England journal of medicine N. Engl. J. Med. Rifaximin therapy for patients with irritable bowel syndrome without constipation. 22-32 10.1056/NEJMoa1004409 Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic (...) , as treatment for IBS. In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS

NEJM2011

103. Two randomized trials of linaclotide for chronic constipation.

Two randomized trials of linaclotide for chronic constipation. 21830967 2011 08 11 2011 08 18 2011 08 11 1533-4406 365 6 2011 Aug 11 The New England journal of medicine N. Engl. J. Med. Two randomized trials of linaclotide for chronic constipation. 527-36 10.1056/NEJMoa1010863 Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation. We conducted two (...) randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials (Trials 303 and 01) involving 1276 patients with chronic constipation. Patients received either placebo or linaclotide, 145 μg or 290 μg, once daily for 12 weeks. The primary efficacy end point was three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks. Adverse events were also monitored. For Trials 303

NEJM2011

104. Systematic review: the effects of fibre in the management of chronic idiopathic constipation

Systematic review: the effects of fibre in the management of chronic idiopathic constipation Systematic review: the effects of fibre in the management of chronic idiopathic constipation Systematic review: the effects of fibre in the management of chronic idiopathic constipation Suares NC, Ford AC CRD summary This review concluded that soluble fibre could aid the management of chronic idiopathic constipation, but the data for insoluble fibre were conflicting, and better evidence was needed (...) for both types of fibre. The limitations of the evidence mean that the authors' conclusions seem appropriate, but the searches were not recent (2010), and further evidence may now be available. Authors' objectives To evaluate the efficacy of soluble or insoluble fibre supplementation in the management of chronic idiopathic constipation. Searching MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched in July (CENTRAL) or September (other databases), 2010

DARE.2011

105. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial

LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

NIHR HTA programme2010

106. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study

Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study 20542295 2010 09 09 2010 10 08 2010 09 09 1097-6833 157 4 2010 Oct The Journal of pediatrics J. Pediatr. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. 598-602 10.1016/j.jpeds.2010.04.066 To evaluate the beneficial effects of Lactobacillus reuteri (DSM 17938) in infants (...) with functional chronic constipation. A double-blind, placebo-controlled, randomized study was conducted from January 2008 to December 2008 in 44 consecutive infants at least 6 months old (mean age+/-SD, 8.2+/-2.4 SD; male/female, 24/20) admitted to the Gastrointestinal Endoscopy and Motility Unit of the Department of Pediatrics, University "Federico II" of Naples, with a diagnosis of functional chronic constipation. The 44 infants with chronic constipation were randomly assigned to 2 groups: group A (n=22

EvidenceUpdates2010

107. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis 20691689 2010 11 01 2010 11 30 2016 12 15 1528-0012 139 5 2010 Nov Gastroenterology Gastroenterology Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. 1549-58, 1558.e1 10.1053/j.gastro.2010.07.052 Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (...) (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C). In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations of placebo, 500 mg CDC, or 1000 mg CDC for 4 days. We assessed gastrointestinal and colonic transit, stool characteristics, and associations of transit with fasting serum 7αC4 (surrogate of bile acid synthesis) and FGF19 (negative regulator

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

108. Abdominal massage for people with constipation: a cost utility analysis

Abdominal massage for people with constipation: a cost utility analysis 20557387 2010 07 23 2010 11 29 2010 07 23 1365-2648 66 8 2010 Aug Journal of advanced nursing J Adv Nurs Abdominal massage for people with constipation: a cost utility analysis. 1719-29 10.1111/j.1365-2648.2010.05339.x This paper is a report of a study conducted to evaluate change in health-related quality of life for people with constipation receiving abdominal massage and to estimate the cost-effectiveness of two (...) alternative scenarios developed from the original trial. Constipation is a common problem and is associated with decrease in quality of life. Abdominal massage appears to decrease the severity of gastrointestinal symptoms, but its impact on health-related quality of life has not been assessed. A randomized controlled trial including 60 participants was conducted in Sweden between 2005 and 2007. The control group continued using laxatives as before and the intervention group received additional abdominal

EvidenceUpdates2010

109. Digital rectal exams in children who present with constipation

Digital rectal exams in children who present with constipation BestBets: Digital rectal exams in children who present with constipation Digital rectal exams in children who present with constipation Report By: Nesba Naheed - Medical Student Search checked by Rachel Jenner - Consultant in Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 5th June 2007 Date Completed: 8th June 2010 Last Modified: 8th June 2010 Status: Green (complete) Three Part Question In a [child (...) presenting with constipation] is a [digital rectal examination] recommended to [confirm the diagnosis]? Clinical Scenario A five year boy is presented to the Emergency department by his mother. His mother complains that he has constipation. After examining the boy's abdomen you wonder whether in order to confirm the diagnosis you should perform a digital rectal exam (DRE). Search Strategy Medline using the OVID interface 1950 to January Week 2 2010: (constipation.mp OR exp Constipation/ exp Feces/ or exp

BestBETS2010

110. The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial

The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial 20207340 2010 05 10 2010 06 01 2013 11 21 1097-6868 202 5 2010 May American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial. 479.e1-5 10.1016/j.ajog.2010.01.003 The objective (...) magnesium citrate AIM IM Citric Acid therapeutic use Constipation drug therapy Dioctyl Sulfosuccinic Acid administration & dosage therapeutic use Double-Blind Method Gynecologic Surgical Procedures Humans Laxatives administration & dosage therapeutic use Organometallic Compounds therapeutic use Pelvic Floor surgery Phytotherapy Postoperative Complications drug therapy Senna Plant Surface-Active Agents 2009 07 10 2009 12 21 2010 01 04 2010 3 9 6 0 2010 3 9 6 0 2010 6 2 6 0 ppublish 20207340 S0002-9378(10

EvidenceUpdates2010

111. Management of constipation.

Management of constipation. Management of constipation. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:007535 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from original guidelines. New on NGC Guideline Summaries Visit our partner

University of Iowa Gerontological Nursing Interventions Research Center, Research Translation and Di2010

112. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation 20179697 2010 04 07 2010 05 06 2015 11 19 1572-0241 105 4 2010 Apr The American journal of gastroenterology Am. J. Gastroenterol. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. 897-903 10.1038/ajg.2010.41 Although it has been used as a laxative for many years, high-quality trials (...) assessing the efficacy of the laxative sodium picosulfate (SPS) are lacking. The purpose of this study was to assess the efficacy and safety of 4-week treatment with SPS in patients with functional constipation as defined by the Rome III diagnostic criteria. This study was a randomized, double-blind, placebo-controlled, parallel-group study in 45 general practices in Germany. A total of 468 patients with chronic constipation presenting to their general practitioner and fulfilling the Rome III diagnostic

EvidenceUpdates2010

113. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK

The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK Taylor RR, Guest JF Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of macrogol 3350, compared with lactulose, for the treatment of chronic constipation in adults. The authors concluded that macrogol 3350 was cost-effective. The methods and the reporting of the results were good

NHS Economic Evaluation Database.2010

114. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation

Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation Belsey JD, Geraint M, Dixon TA CRD summary This review concluded that polyethylene glycol was more effective than lactulose for the treatment of adults with non-organic constipation. Overall, the findings (...) of the review appear valid, but the risk of missing data and lack of detail regarding the review methods made the reliability unclear. Authors' objectives To compare the efficacy of polyethylene glycol (PEG) versus placebo or active comparators for the treatment of non-organic constipation in adults. Searching MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials (CENTRAL) databases and Google Scholar were searched for studies published in peer-reviewed journals from January 1970

DARE.2010

115. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial

LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P (...) , Rubin G, Steen IN, McColl E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P, Rubin G, Steen IN, McColl E. LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial. Health

Health Technology Assessment (HTA) Database.2010

116. Methylnaltrexone (Relistor) for opioid-induced constipation

Methylnaltrexone (Relistor) for opioid-induced constipation 2010. DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation Content tools Share it Subcutaneous route instead of suppository or enema in terminal patients The use

Drug and Therapeutics Bulletin of Navarre (Spain)2010

117. Prucalopride for the treatment of chronic constipation in women

Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Prucalopride (...) for the treatment of chronic constipation in women. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 211. 2010 Authors' conclusions Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered

Health Technology Assessment (HTA) Database.2010

118. Prucalopride for the treatment of chronic constipation in women (TA211)

Prucalopride for the treatment of chronic constipation in women (TA211) Prucalopride for the treatment of chronic constipation in women | Guidance and guidelines | NICE Prucalopride for the treatment of chronic constipation in women Technology appraisal guidance [TA211] Published date: 15 December 2010 Share Guidance on prucalopride (Resolor) for treating chronic constipation in women. Guidance development process Is this guidance up to date? . We found nothing new that affects

National Institute for Health and Clinical Excellence - Technology Appraisals2010

119. Constipation

Constipation © 2010, Dutch College of General Practitioners www.nhg.org Appendix to H&W, 2010, 53, No. 9, page 484 september 2010 Constipation in adults is diagnosed if there are at least two of the following symptoms: ? defecation frequency = 2 per week; ? increased straining during defecation; ? hard and/or pebble -like defecation; ? feeling of incomple te defecation; ? feeling of anorecta l obstruction/blockage; ? manual manoeuvres to facilitate defecation. Constipation in children (...) to promote defecation; incomplete defecation; dif ficult faecal passage; indications of irritable bowel syndrome). ? Diet (suf ficient fluid intake; suf ficient fibre intake). ? Causal factors and consequences (pain during defecation; rectal blood loss; use of laxatives and medication with constipation as a side ef fect; hypothyroidism, diabetes mellitus, pregnancy , Parkinson's disease, multiple sclerosis). ? General symptoms: increasing abdominal pain and vomiting, discomfort, weight loss. Additional

Dutch College of General Practitioners (NHG)2010

120. Constipation in children and young people: diagnosis and management

Constipation in children and young people: diagnosis and management Constipation in children and y Constipation in children and young oung people: diagnosis and management people: diagnosis and management Clinical guideline Published: 26 May 2010 nice.org.uk/guidance/cg99 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Constipation in children and young people: diagnosis and management (CG99) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

National Institute for Health and Clinical Excellence - Clinical Guidelines2010